A Phase II, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Epidemiology of Natural Infection With Enterotoxigenic Escherichia Coli Occurring After Transcutaneous Immunization in a Field Setting.

Trial Profile

A Phase II, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Epidemiology of Natural Infection With Enterotoxigenic Escherichia Coli Occurring After Transcutaneous Immunization in a Field Setting.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Escherichia coli vaccine (Primary)
  • Indications Escherichia coli infections; Traveller's diarrhoea
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TREK
  • Sponsors Intercell USA; Valneva USA
  • Most Recent Events

    • 11 Dec 2017 According to a Valneva media release, Intercell USA changed its name to Valneva USA.
    • 13 Mar 2012 Additional location (USA) added as reported by ClinicalTrials.gov.
    • 13 Mar 2012 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top